White Paper
Semaglutide LOE in India
A rare opportunity demanding a new playbook
Oct 28, 2025
India's upcoming Loss of Exclusivity (LOE) for semaglutide marks a pivotal moment in global obesity care—one that is likely to defy traditional generics playbooks and demand bold, innovative strategies. With over 150 million potential patients, a fast-growing self-pay market, and early patent expiry, India creates a unique environment where both generics and innovators will shape new commercial and therapeutic norms. Unlike previous LOEs, this event is defined by rapid market evolution, rising patient influence, and complex pricing dynamics, with India poised to become a strategic hub for GLP-1 manufacturing and a blueprint for emerging markets. Success will depend on innovative strategies that go beyond price competition, focusing on patient engagement, digital channels, and tailored solutions for diverse obesity segments. Read our white paper to learn more.
Contact Us